Optimizing Donor & Starting‑Line Selection to Enhance iPSC Quality & Reduce Downstream Variability
- Building multi‑donor and multi‑clone assessment frameworks to prevent over‑reliance on a single source and reduce variability
- Identifying donor‑derived biases: how age, source material, and intrinsic biology predispose iPSCs to certain lineages
- Navigating preclinical ethical and regulatory constraints that can stall animal work or destabilize program timelines